Literature DB >> 10633490

Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus.

K Fujimaki1, S Morinobu, R S Duman.   

Abstract

The influence of two selective phosphodiesterase 4 (PDE4) inhibitors, rolipram and Ro 20-1724, on the induction of BDNF mRNA by antidepressant treatment was examined. Coadministration of rolipram or Ro 20-1724 with an antidepressant (either desipramine or Org 4428) for 21 d resulted in a significant induction of BDNF mRNA in hippocampus relative to administration of vehicle. Coadministration of a PDE4 inhibitor with an antidepressant for 7 or 14 d also increased levels of BDNF mRNA. In contrast, acute coadministration did not influence levels of BDNF mRNA. In situ hybridization analysis demonstrated that the induction of BDNF mRNA in response to the repeated coadministration paradigm occurs in the dentate gyrus granule and CA1 and CA3 pyramidal cell layers of hippocampus. These findings demonstrate that coadministration shortens the time required for the upregulation of BDNF mRNA, supporting the possibility that this treatment may provide an effective therapy for major depression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10633490     DOI: 10.1016/S0893-133X(99)00084-6

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  26 in total

1.  Antagonism of the antidepressant-like effects of clenbuterol by central administration of beta-adrenergic antagonists in rats.

Authors:  Han-Ting Zhang; Ying Huang; James M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2003-07-25       Impact factor: 4.530

Review 2.  From synapse to nucleus: novel targets for treating depression.

Authors:  Herbert E Covington; Vincent Vialou; Eric J Nestler
Journal:  Neuropharmacology       Date:  2009-12-17       Impact factor: 5.250

3.  RNA interference-mediated phosphodiesterase 4D splice variants knock-down in the prefrontal cortex produces antidepressant-like and cognition-enhancing effects.

Authors:  Zhen-Zhen Wang; Yi Zhang; Yan-Qin Liu; Nan Zhao; You-Zhi Zhang; Li Yuan; Lei An; Jing Li; Xiao-Yun Wang; Juan-Juan Qin; Steven P Wilson; James M O'Donnell; Han-Ting Zhang; Yun-Feng Li
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

Review 4.  Neurotrophin strategies for neuroprotection: are they sufficient?

Authors:  Joseph P Steiner; Avindra Nath
Journal:  J Neuroimmune Pharmacol       Date:  2014-03-08       Impact factor: 4.147

5.  Swim everyday to keep dementia away.

Authors:  Milind Parle; Mani Vasudevan; Nirmal Singh
Journal:  J Sports Sci Med       Date:  2005-03-01       Impact factor: 2.988

6.  Running exercise-induced up-regulation of hippocampal brain-derived neurotrophic factor is CREB-dependent.

Authors:  Michael J Chen; Amelia A Russo-Neustadt
Journal:  Hippocampus       Date:  2009-10       Impact factor: 3.899

Review 7.  Role of neurotrophic factors in the etiology and treatment of mood disorders.

Authors:  Ronald S Duman
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

8.  Brain-derived neurotrophic factor: role in depression and suicide.

Authors:  Yogesh Dwivedi
Journal:  Neuropsychiatr Dis Treat       Date:  2009-08-20       Impact factor: 2.570

9.  Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis.

Authors:  D Taliaz; N Stall; D E Dar; A Zangen
Journal:  Mol Psychiatry       Date:  2009-07-21       Impact factor: 15.992

10.  Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus.

Authors:  Yun-Feng Li; Ying Huang; Simon L Amsdell; Lan Xiao; James M O'Donnell; Han-Ting Zhang
Journal:  Neuropsychopharmacology       Date:  2009-06-10       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.